Rocket Pharmaceuticals, Inc. Available-for-sale Securities, Gross Unrealized Loss
Rocket Pharmaceuticals, Inc. (RCKT) reported Available-for-sale Securities, Gross Unrealized Loss of $16.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2018-03-07
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2017-12-31 was -$9.00K, a 118.75% decline year-over-year.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2017-09-30 was -$47.00K.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2017-06-30 was $0.00.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2017-03-31 was $72.00K, a 2300.00% increase year-over-year.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized loss for fiscal 2017 was $16.00K, a 70.91% decline from fiscal 2016.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized loss for fiscal 2016 was $55.00K, a 400.00% increase from fiscal 2015.
- Rocket Pharmaceuticals, Inc. available-for-sale securities, gross unrealized loss for fiscal 2015 was $11.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$56.00K derived: sum of 2 quarters · filed 2018-03-07 | -$56.00K derived: sum of 3 quarters · filed 2018-03-07 | $16.00K 10-K · filed 2018-03-07 |
| 2017-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$47.00K derived: sum of 2 quarters · filed 2017-11-08 | $25.00K 10-Q · filed 2017-11-08 | $73.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $72.00K 10-Q · filed 2017-08-03 | $120.00K derived: sum of 3 quarters · filed 2018-03-07 | |
| 2017-03-31 | $72.00K 10-Q · filed 2017-05-10 | $120.00K derived: sum of 2 quarters · filed 2018-03-07 | ||
| 2016-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $55.00K 10-K · filed 2018-03-07 | ||
| 2016-09-30 | $7.00K 10-Q · filed 2016-11-09 | |||
| 2016-03-31 | $3.00K 10-Q · filed 2016-05-11 | $13.00K derived: sum of 2 quarters · filed 2017-03-16 | ||
| 2015-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $11.00K 10-K · filed 2017-03-16 | ||
| 2015-09-30 | $1.00K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |